APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid Antagonist

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Opioid Antagonist Industry Growth and Trends Forecast to 2032

19 December 2025104 pages

Choose your research edition.

Industry ResearchOpioid Antagonist Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Antagonist Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Opioid Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Antagonist Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Antagonist Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Opioid Antagonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioid Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Opioid Antagonist include Titan Pharmaceuticals, AstraZeneca, Shionogi, Orexo, Opiant Pharmaceuticals, Indivior, Hikma Pharmaceuticals, Collegium Pharmaceutical and Camurus, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Opioid Antagonist market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Opioid Antagonist market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Opioid Antagonist market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Opioid Antagonist.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Opioid Antagonist market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Opioid Antagonist Market by Company

Titan Pharmaceuticals

AstraZeneca

Shionogi

Orexo

Opiant Pharmaceuticals

Indivior

Hikma Pharmaceuticals

Collegium Pharmaceutical

Camurus

BioDelivery Sciences International

Alkermes

Acura Pharmaceuticals

Opioid Antagonist Segment by Type

Oral

Parenteral

Opioid Antagonist Segment by Application

Hospitals

Clinics

Others

Opioid Antagonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Opioid Antagonist manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Opioid Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral Table 2. Major Company of Parenteral Table 3. Global Opioid Antagonist Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Opioid Antagonist Sales by Type (2021-2026) & (K Units) Table 5. Global Opioid Antagonist Sales Market Share in Volume by Type (2021-2026) Table 6. Global Opioid Antagonist Sales by Type (2021-2026) & (US$ Million) Table 7. Global Opioid Antagonist Sales Market Share in Value by Type (2021-2026) Table 8. Global Opioid Antagonist Price by Type (2021-2026) & (US$/Unit) Table 9. Global Opioid Antagonist Sales by Type (2027-2032) & (K Units) Table 10. Global Opioid Antagonist Sales Market Share in Volume by Type (2027-2032) Table 11. Global Opioid Antagonist Sales by Type (2027-2032) & (US$ Million) Table 12. Global Opioid Antagonist Sales Market Share in Value by Type (2027-2032) Table 13. Global Opioid Antagonist Price by Type (2027-2032) & (US$/Unit) Table 14. North America Opioid Antagonist Sales by Type (2021-2026) & (K Units) Table 15. North America Opioid Antagonist Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Opioid Antagonist Sales by Type (2021-2026) & (K Units) Table 17. Europe Opioid Antagonist Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Opioid Antagonist Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Opioid Antagonist Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Opioid Antagonist Sales by Type (2021-2026) & (K Units) Table 21. Latin America Opioid Antagonist Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Opioid Antagonist Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Opioid Antagonist Sales by Type (2021-2026) & (US$ Million) Table 24. Opioid Antagonist Industry Trends Table 25. Opioid Antagonist Industry Drivers Table 26. Opioid Antagonist Industry Opportunities and Challenges Table 27. Opioid Antagonist Industry Restraints Table 28. Global Opioid Antagonist Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Opioid Antagonist Revenue Market Share by Company (2021-2026) Table 30. Global Opioid Antagonist Sales by Company (2021-2026) & (K Units) Table 31. Global Opioid Antagonist Sales Share by Company (2021-2026) Table 32. Global Opioid Antagonist Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Opioid Antagonist Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Opioid Antagonist Major Company Production Sites and Headquarters Table 35. Global Opioid Antagonist Company, Product Type & Application Table 36. Global Opioid Antagonist Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Opioid Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Opioid Antagonist Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Opioid Antagonist Sales by Region (2021-2026) & (K Units) Table 41. Global Opioid Antagonist Sales Market Share in Volume by Region (2021-2026) Table 42. Global Opioid Antagonist Sales by Region (2021-2026) & (US$ Million) Table 43. Global Opioid Antagonist Sales Market Share in Value by Region (2021-2026) Table 44. Global Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Opioid Antagonist Sales by Region (2027-2032) & (K Units) Table 46. Global Opioid Antagonist Sales Market Share in Volume by Region (2027-2032) Table 47. Global Opioid Antagonist Sales by Region (2027-2032) & (US$ Million) Table 48. Global Opioid Antagonist Sales Market Share in Value by Region (2027-2032) Table 49. Global Opioid Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Opioid Antagonist Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Opioid Antagonist Sales by Application (2021-2026) & (K Units) Table 52. Global Opioid Antagonist Sales Market Share in Volume by Application (2021-2026) Table 53. Global Opioid Antagonist Sales by Application (2021-2026) & (US$ Million) Table 54. Global Opioid Antagonist Sales Market Share in Value by Application (2021-2026) Table 55. Global Opioid Antagonist Price by Application (2021-2026) & (US$/Unit) Table 56. Global Opioid Antagonist Sales by Application (2027-2032) & (K Units) Table 57. Global Opioid Antagonist Sales Market Share in Volume by Application (2027-2032) Table 58. Global Opioid Antagonist Sales by Application (2027-2032) & (US$ Million) Table 59. Global Opioid Antagonist Sales Market Share in Value by Application (2027-2032) Table 60. Global Opioid Antagonist Price by Application (2027-2032) & (US$/Unit) Table 61. North America Opioid Antagonist Sales by Application (2021-2026) & (K Units) Table 62. North America Opioid Antagonist Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Opioid Antagonist Sales by Application (2021-2026) & (K Units) Table 64. Europe Opioid Antagonist Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Opioid Antagonist Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Opioid Antagonist Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Opioid Antagonist Sales by Application (2021-2026) & (K Units) Table 68. Latin America Opioid Antagonist Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Opioid Antagonist Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Opioid Antagonist Sales by Application (2021-2026) & (US$ Million) Table 71. Titan Pharmaceuticals Company Information Table 72. Titan Pharmaceuticals Business Overview Table 73. Titan Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Titan Pharmaceuticals Opioid Antagonist Product Portfolio Table 75. Titan Pharmaceuticals Recent Development Table 76. AstraZeneca Company Information Table 77. AstraZeneca Business Overview Table 78. AstraZeneca Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. AstraZeneca Opioid Antagonist Product Portfolio Table 80. AstraZeneca Recent Development Table 81. Shionogi Company Information Table 82. Shionogi Business Overview Table 83. Shionogi Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Shionogi Opioid Antagonist Product Portfolio Table 85. Shionogi Recent Development Table 86. Orexo Company Information Table 87. Orexo Business Overview Table 88. Orexo Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Orexo Opioid Antagonist Product Portfolio Table 90. Orexo Recent Development Table 91. Opiant Pharmaceuticals Company Information Table 92. Opiant Pharmaceuticals Business Overview Table 93. Opiant Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Opiant Pharmaceuticals Opioid Antagonist Product Portfolio Table 95. Opiant Pharmaceuticals Recent Development Table 96. Indivior Company Information Table 97. Indivior Business Overview Table 98. Indivior Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Indivior Opioid Antagonist Product Portfolio Table 100. Indivior Recent Development Table 101. Hikma Pharmaceuticals Company Information Table 102. Hikma Pharmaceuticals Business Overview Table 103. Hikma Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Hikma Pharmaceuticals Opioid Antagonist Product Portfolio Table 105. Hikma Pharmaceuticals Recent Development Table 106. Collegium Pharmaceutical Company Information Table 107. Collegium Pharmaceutical Business Overview Table 108. Collegium Pharmaceutical Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Collegium Pharmaceutical Opioid Antagonist Product Portfolio Table 110. Collegium Pharmaceutical Recent Development Table 111. Camurus Company Information Table 112. Camurus Business Overview Table 113. Camurus Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Camurus Opioid Antagonist Product Portfolio Table 115. Camurus Recent Development Table 116. BioDelivery Sciences International Company Information Table 117. BioDelivery Sciences International Business Overview Table 118. BioDelivery Sciences International Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. BioDelivery Sciences International Opioid Antagonist Product Portfolio Table 120. BioDelivery Sciences International Recent Development Table 121. Alkermes Company Information Table 122. Alkermes Business Overview Table 123. Alkermes Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Alkermes Opioid Antagonist Product Portfolio Table 125. Alkermes Recent Development Table 126. Acura Pharmaceuticals Company Information Table 127. Acura Pharmaceuticals Business Overview Table 128. Acura Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Acura Pharmaceuticals Opioid Antagonist Product Portfolio Table 130. Acura Pharmaceuticals Recent Development Table 131. North America Opioid Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 132. North America Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 133. North America Opioid Antagonist Sales Market Share by Country (2021-2026) Table 134. North America Opioid Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 135. North America Opioid Antagonist Sales Market Share Forecast by Country (2027-2032) Table 136. North America Opioid Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. North America Opioid Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 138. North America Opioid Antagonist Market Share by Country (2021-2026) Table 139. North America Opioid Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. North America Opioid Antagonist Market Share Forecast by Country (2027-2032) Table 141. Europe Opioid Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 142. Europe Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 143. Europe Opioid Antagonist Sales Market Share by Country (2021-2026) Table 144. Europe Opioid Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 145. Europe Opioid Antagonist Sales Market Share Forecast by Country (2027-2032) Table 146. Europe Opioid Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Europe Opioid Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 148. Europe Opioid Antagonist Market Share by Country (2021-2026) Table 149. Europe Opioid Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Europe Opioid Antagonist Market Share Forecast by Country (2027-2032) Table 151. Asia-Pacific Opioid Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 152. Asia-Pacific Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 153. Asia-Pacific Opioid Antagonist Sales Market Share by Country (2021-2026) Table 154. Asia-Pacific Opioid Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 155. Asia-Pacific Opioid Antagonist Sales Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Opioid Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Opioid Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 158. Asia-Pacific Opioid Antagonist Market Share by Country (2021-2026) Table 159. Asia-Pacific Opioid Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Asia-Pacific Opioid Antagonist Market Share Forecast by Country (2027-2032) Table 161. Latin America Opioid Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. Latin America Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 163. Latin America Opioid Antagonist Sales Market Share by Country (2021-2026) Table 164. Latin America Opioid Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 165. Latin America Opioid Antagonist Sales Market Share Forecast by Country (2027-2032) Table 166. Latin America Opioid Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Latin America Opioid Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 168. Latin America Opioid Antagonist Market Share by Country (2021-2026) Table 169. Latin America Opioid Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Latin America Opioid Antagonist Market Share Forecast by Country (2027-2032) Table 171. Middle East and Africa Opioid Antagonist Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Middle East and Africa Opioid Antagonist Sales by Country (2021-2026) & (K Units) Table 173. Middle East and Africa Opioid Antagonist Sales Market Share by Country (2021-2026) Table 174. Middle East and Africa Opioid Antagonist Sales Forecast by Country (2027-2032) & (K Units) Table 175. Middle East and Africa Opioid Antagonist Sales Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Opioid Antagonist Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Opioid Antagonist Market Size by Country (2021-2026) & (US$ Million) Table 178. Middle East and Africa Opioid Antagonist Market Share by Country (2021-2026) Table 179. Middle East and Africa Opioid Antagonist Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Middle East and Africa Opioid Antagonist Market Share Forecast by Country (2027-2032) Table 181. Key Raw Materials Table 182. Raw Materials Key Suppliers Table 183. Opioid Antagonist Distributors List Table 184. Opioid Antagonist Customers List Table 185. Research Programs/Design for This Report Table 186. Authors List of This Report Table 187. Secondary Sources Table 188. Primary Sources List of Figures Figure 1. Opioid Antagonist Image Figure 2. Global Opioid Antagonist Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Antagonist Market Size (2021-2032) & (US$ Million) Figure 4. Global Opioid Antagonist Sales (2021-2032) & (K Units) Figure 5. Oral Image Figure 6. Global Oral Sales YoY Growth (2021-2032) & (K Units) Figure 7. Parenteral Image Figure 8. Global Parenteral Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Opioid Antagonist Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Opioid Antagonist Market Share by Type 2025 VS 2032 Figure 11. North America Opioid Antagonist Sales Market Share in Volume by Type in 2025 Figure 12. North America Opioid Antagonist Sales Market Share in Value by Type in 2025 Figure 13. Europe Opioid Antagonist Sales Market Share in Volume by Type in 2025 Figure 14. Europe Opioid Antagonist Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Opioid Antagonist Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Opioid Antagonist Sales Market Share in Value by Type in 2025 Figure 17. Latin America Opioid Antagonist Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Opioid Antagonist Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Opioid Antagonist Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Opioid Antagonist Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Opioid Antagonist Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospitals Image Figure 24. Global Hospitals Sales YoY Growth (2021-2032) & (K Units) Figure 25. Clinics Image Figure 26. Global Clinics Sales YoY Growth (2021-2032) & (K Units) Figure 27. Others Image Figure 28. Global Others Sales YoY Growth (2021-2032) & (K Units) Figure 29. Global Opioid Antagonist Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Opioid Antagonist Market Share by Application 2025 VS 2032 Figure 31. North America Opioid Antagonist Sales Market Share in Volume by Application in 2025 Figure 32. North America Opioid Antagonist Sales Market Share in Value by Application in 2025 Figure 33. Europe Opioid Antagonist Sales Market Share in Volume by Application in 2025 Figure 34. Europe Opioid Antagonist Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Opioid Antagonist Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Opioid Antagonist Sales Market Share in Value by Application in 2025 Figure 37. Latin America Opioid Antagonist Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Opioid Antagonist Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Opioid Antagonist Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Opioid Antagonist Sales Market Share in Value by Application in 2025 Figure 41. North America Opioid Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 42. North America Opioid Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Opioid Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Opioid Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. Europe Opioid Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Opioid Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Opioid Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Asia-Pacific Opioid Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Opioid Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Opioid Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Latin America Opioid Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Opioid Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Opioid Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Middle East and Africa Opioid Antagonist Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Opioid Antagonist Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Opioid Antagonist Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Opioid Antagonist Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Opioid Antagonist Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Parenteral
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Titan Pharmaceuticals
  • AstraZeneca
  • Shionogi
  • Orexo
  • Opiant Pharmaceuticals
  • Indivior
  • Hikma Pharmaceuticals
  • Collegium Pharmaceutical
  • Camurus
  • BioDelivery Sciences International
  • Alkermes
  • Acura Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Opioid Antagonist Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Opioid Antagonist Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Opioid Antagonist Market by Type
  6. 1.3.1 Oral
  7. 1.3.2 Parenteral
  8. 1.4 Global Opioid Antagonist Market Size by Type
  9. 1.4.1 Global Opioid Antagonist Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Opioid Antagonist Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Opioid Antagonist Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Opioid Antagonist Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Opioid Antagonist Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Opioid Antagonist Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Opioid Antagonist Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Opioid Antagonist Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Opioid Antagonist Industry Trends
  2. 2.2 Opioid Antagonist Industry Drivers
  3. 2.3 Opioid Antagonist Industry Opportunities and Challenges
  4. 2.4 Opioid Antagonist Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Opioid Antagonist Revenue (2021-2026)
  2. 3.2 Global Top Players by Opioid Antagonist Sales (2021-2026)
  3. 3.3 Global Top Players by Opioid Antagonist Price (2021-2026)
  4. 3.4 Global Opioid Antagonist Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Opioid Antagonist Major Company Production Sites & Headquarters
  6. 3.6 Global Opioid Antagonist Company, Product Type & Application
  7. 3.7 Global Opioid Antagonist Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Opioid Antagonist Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Opioid Antagonist Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Opioid Antagonist Tier 1, Tier 2, and Tier 3
4 Opioid Antagonist Regional Status and Outlook
  1. 4.1 Global Opioid Antagonist Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Opioid Antagonist Historic Market Size by Region
  3. 4.2.1 Global Opioid Antagonist Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Opioid Antagonist Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Opioid Antagonist Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Opioid Antagonist Forecasted Market Size by Region
  7. 4.3.1 Global Opioid Antagonist Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Opioid Antagonist Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Opioid Antagonist Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Opioid Antagonist by Application
  1. 5.1 Opioid Antagonist Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Opioid Antagonist Market Size by Application
  6. 5.2.1 Global Opioid Antagonist Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Opioid Antagonist Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Opioid Antagonist Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Opioid Antagonist Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Opioid Antagonist Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Opioid Antagonist Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Opioid Antagonist Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Opioid Antagonist Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Titan Pharmaceuticals
  2. 6.1.1 Titan Pharmaceuticals Company Information
  3. 6.1.2 Titan Pharmaceuticals Business Overview
  4. 6.1.3 Titan Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Titan Pharmaceuticals Opioid Antagonist Product Portfolio
  6. 6.1.5 Titan Pharmaceuticals Recent Developments
  7. 6.2 AstraZeneca
  8. 6.2.1 AstraZeneca Company Information
  9. 6.2.2 AstraZeneca Business Overview
  10. 6.2.3 AstraZeneca Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 AstraZeneca Opioid Antagonist Product Portfolio
  12. 6.2.5 AstraZeneca Recent Developments
  13. 6.3 Shionogi
  14. 6.3.1 Shionogi Company Information
  15. 6.3.2 Shionogi Business Overview
  16. 6.3.3 Shionogi Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Shionogi Opioid Antagonist Product Portfolio
  18. 6.3.5 Shionogi Recent Developments
  19. 6.4 Orexo
  20. 6.4.1 Orexo Company Information
  21. 6.4.2 Orexo Business Overview
  22. 6.4.3 Orexo Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Orexo Opioid Antagonist Product Portfolio
  24. 6.4.5 Orexo Recent Developments
  25. 6.5 Opiant Pharmaceuticals
  26. 6.5.1 Opiant Pharmaceuticals Company Information
  27. 6.5.2 Opiant Pharmaceuticals Business Overview
  28. 6.5.3 Opiant Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Opiant Pharmaceuticals Opioid Antagonist Product Portfolio
  30. 6.5.5 Opiant Pharmaceuticals Recent Developments
  31. 6.6 Indivior
  32. 6.6.1 Indivior Company Information
  33. 6.6.2 Indivior Business Overview
  34. 6.6.3 Indivior Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Indivior Opioid Antagonist Product Portfolio
  36. 6.6.5 Indivior Recent Developments
  37. 6.7 Hikma Pharmaceuticals
  38. 6.7.1 Hikma Pharmaceuticals Company Information
  39. 6.7.2 Hikma Pharmaceuticals Business Overview
  40. 6.7.3 Hikma Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Hikma Pharmaceuticals Opioid Antagonist Product Portfolio
  42. 6.7.5 Hikma Pharmaceuticals Recent Developments
  43. 6.8 Collegium Pharmaceutical
  44. 6.8.1 Collegium Pharmaceutical Company Information
  45. 6.8.2 Collegium Pharmaceutical Business Overview
  46. 6.8.3 Collegium Pharmaceutical Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Collegium Pharmaceutical Opioid Antagonist Product Portfolio
  48. 6.8.5 Collegium Pharmaceutical Recent Developments
  49. 6.9 Camurus
  50. 6.9.1 Camurus Company Information
  51. 6.9.2 Camurus Business Overview
  52. 6.9.3 Camurus Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Camurus Opioid Antagonist Product Portfolio
  54. 6.9.5 Camurus Recent Developments
  55. 6.10 BioDelivery Sciences International
  56. 6.10.1 BioDelivery Sciences International Company Information
  57. 6.10.2 BioDelivery Sciences International Business Overview
  58. 6.10.3 BioDelivery Sciences International Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 BioDelivery Sciences International Opioid Antagonist Product Portfolio
  60. 6.10.5 BioDelivery Sciences International Recent Developments
  61. 6.11 Alkermes
  62. 6.11.1 Alkermes Company Information
  63. 6.11.2 Alkermes Business Overview
  64. 6.11.3 Alkermes Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Alkermes Opioid Antagonist Product Portfolio
  66. 6.11.5 Alkermes Recent Developments
  67. 6.12 Acura Pharmaceuticals
  68. 6.12.1 Acura Pharmaceuticals Company Information
  69. 6.12.2 Acura Pharmaceuticals Business Overview
  70. 6.12.3 Acura Pharmaceuticals Opioid Antagonist Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Acura Pharmaceuticals Opioid Antagonist Product Portfolio
  72. 6.12.5 Acura Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Opioid Antagonist Sales by Country
  2. 7.1.1 North America Opioid Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Opioid Antagonist Sales by Country (2021-2026)
  4. 7.1.3 North America Opioid Antagonist Sales Forecast by Country (2027-2032)
  5. 7.2 North America Opioid Antagonist Market Size by Country
  6. 7.2.1 North America Opioid Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Opioid Antagonist Market Size by Country (2021-2026)
  8. 7.2.3 North America Opioid Antagonist Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Opioid Antagonist Sales by Country
  2. 8.1.1 Europe Opioid Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Opioid Antagonist Sales by Country (2021-2026)
  4. 8.1.3 Europe Opioid Antagonist Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Opioid Antagonist Market Size by Country
  6. 8.2.1 Europe Opioid Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Opioid Antagonist Market Size by Country (2021-2026)
  8. 8.2.3 Europe Opioid Antagonist Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Opioid Antagonist Sales by Country
  2. 9.1.1 Asia-Pacific Opioid Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Opioid Antagonist Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Opioid Antagonist Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Opioid Antagonist Market Size by Country
  6. 9.2.1 Asia-Pacific Opioid Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Opioid Antagonist Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Opioid Antagonist Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Opioid Antagonist Sales by Country
  2. 10.1.1 South America Opioid Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Opioid Antagonist Sales by Country (2021-2026)
  4. 10.1.3 South America Opioid Antagonist Sales Forecast by Country (2027-2032)
  5. 10.2 South America Opioid Antagonist Market Size by Country
  6. 10.2.1 South America Opioid Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Opioid Antagonist Market Size by Country (2021-2026)
  8. 10.2.3 South America Opioid Antagonist Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Opioid Antagonist Sales by Country
  2. 11.1.1 Middle East and Africa Opioid Antagonist Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Opioid Antagonist Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Opioid Antagonist Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Opioid Antagonist Market Size by Country
  6. 11.2.1 Middle East and Africa Opioid Antagonist Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Opioid Antagonist Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Opioid Antagonist Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Opioid Antagonist Value Chain Analysis
  2. 12.1.1 Opioid Antagonist Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Opioid Antagonist Production Mode & Process
  7. 12.2 Opioid Antagonist Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Opioid Antagonist Distributors
  10. 12.2.3 Opioid Antagonist Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst